Identification of strong correlations of clearance with clinical outcomes for inflammatory bowel disease

doi:10.3748/wjg.v32.i5.113505

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 5

This Article

(37)

(40)

(0)

(899)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Feb 7, 2026; 32(5): 113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505

Full Size Figure Download Figure

Figure 4 Observed vs predicted serum infliximab concentrations and C-reactive protein and fecal calprotectin levels. A: Patient 3; B: Patient 4; C: Patient 9. In each figure panel: Serum infliximab (IFX) concentrations, solid lines show individual predicted values, filled circles show observed concentrations, and dashed lines shows the target threshold. CRP: C-reactive protein; FCP: Fecal calprotectin.

Citation: Mould DR, Kutschera M, Primas C, Reinisch S, Novacek G, Lichtenberger C, Dervieux T, Bae Y, Lee SH, Lee JH, Reinisch W. Identification of strong correlations of clearance with clinical outcomes for inflammatory bowel disease. World J Gastroenterol 2026; 32(5): 113505
URL: https://www.wjgnet.com/1007-9327/full/v32/i5/113505.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i5.113505

Mould DR, Kutschera M, Primas C, Reinisch S, Novacek G, Lichtenberger C, Dervieux T, Bae Y, Lee SH, Lee JH, Reinisch W. Identification of strong correlations of clearance with clinical outcomes for inflammatory bowel disease. World J Gastroenterol 2026; 32(5): 113505 [PMID: 41693973 DOI: 10.3748/wjg.v32.i5.113505]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.